Recent Event Highlights: PDT, EVCA, JNJ, JCI - DoubleInStocks.com Presents Friday's Stock Report Update! - Penny Stock Live, Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit Against ... - MarketWatch (press release), J&J Shares Dip on Capitol Hill Grilling - Barron's (blog), AMZN, MSFT, JNJ, WAG, PEP - Volume Actives with Negative closing - Penny Stock Live, Stock Market News Briefs: Colgate-Palmolive Company, Goldman Sachs Group ... - Daily Markets, Clean up with Johnson & Johnson stock - Emailwire (press release), and 103 more...
Created by dipity on Jul 22, 2009
Last updated: 10/31/10 at 01:51 AM
Jnj Stock has no followers yet. Be the first one to follow.
PDT, EVCA, JNJ, JCI - DoubleInStocks.com Presents Friday's Stock Report Update!Penny Stock LiveIf you purchased J&J securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 22, 2010. ...
Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit Against ...MarketWatch (press release)If you purchased J&J securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 22, 2010. ...and more »
MiamiHerald.comJ&J Shares Dip on Capitol Hill GrillingBarron's (blog)Johnson & Johnson (JNJ) stock is holding up fairly well today as the company's CEO, William Weldon, was grilled by the House Committee on ...J&J admits misleading US Motrin recallReutersJohnson & Johnson Accused Of Acting Too Slowly In Motrin Recall By FDA (JNJ)Comtex SmartrendJohnson & Johnson CEO Says Co. 'Let The Public Down' On Tylenol Contamination ...Comtex SmartrendTrading Markets (press release)all 871 news articles »
AMZN, MSFT, JNJ, WAG, PEP - Volume Actives with Negative closingPenny Stock LiveStockBlizzard.com is a leading stock web site that provides free alerts on stocks that are making big gains, as well as our weekly Newsletter. ...and more »
Stock Market News Briefs: Colgate-Palmolive Company, Goldman Sachs Group ...Daily MarketsUS Lawmakers will take Johnson & Johnson's (NYSE:JNJ) CEO to task today over their recall of faulty medicines. Yahoo (NASDAQ:YHOO) has joined companies ...and more »
Clean up with Johnson & Johnson stockEmailwire (press release)The Consolidated Investment Analysis on Johnson & Johnson (NYSE:JNJ) will be in particular interest to other competing companys within in its sector, ...3 Most Active Healthcare Stocks in Mid-Day TradingBeacon Equity Researchall 5 news articles »
htttp://www.StockmarketFunding.com HBI Nasdaq Biotech Rally FDA Panel Updates. HGSI, DNDN, BMY, JNJ, BCRX, CELG, AZN, MRK, PFE and other selected biotechnology stocks trade in the biotech index. "The stock market" posted these games as "big money" moved into the markets and "stocks trading"...
"The CEO of Johnson & Johnson (NYSE:JNJ) responded to recent reports of its transgressions on its Children's Tylenol contamination, saying to congress that his company ""let the public down"" in its handling of the recalls. During a prepared testimony, the J&J CEO William Weldon also suggested the company made a serious misstep last year when it hired contractors to purchase bottles of defective lots of Motrin. SmarTrend is bullish on shares of Johnson & Johnson and our subscribers were alerted to buy on September 14, 2010 at $60.61. The stock has risen 2.8% since the alert was issued."
JNJ, PG, SYMC, WMT, SLE – Stocks in ReviewPenny Stock Live(PennystockLive.com, September 29, 2010) Johnson & Johnson NYSE:JNJ gained by 0.64% closed at $62.43 with total traded volume of 12.16 million shares for ...
New Acquisition For Johnson & Johnson (NYSE:JNJ)Stock BriefingsJohnson & Johnson (NYSE:JNJ) has announced the completion of a cash deal for Micrus Endovascular. Johnson & Johnson (NYSE:JNJ) stocks stood at 62.03 at the ...Johnson & Johnson completes acquisition of Micrus EndovascularTrading Markets (press release)Johnson & Johnson Completes Acquisition Of Micrus EndovascularDaily Marketsall 41 news articles »
"Amgen (NASDAQ:AMGN) announced Friday that it was recalling certain lots of its anemia drug Procrit and Epogen due to concerns that glass from the inside of drug's vial could flake off over time. Amgen sells Epogen in the US and Johnson & Johnson (NYSE:JNJ) unit Centocor distributes Procrit in the US. Amgen said, thus far, no adverse occurrences have been called in, but that glass flakes in the drug could generate blood clots. SmarTrend is bullish on shares of Amgen and our subscribers were alerted to buy on September 10, 2010 at $54.16. The stock has risen 3.5% since the alert was issued."
Volume Spikes of the day (JNJ, JPM, KFT, MDT, MRK )Penny Stock Live(PennystockLive.com, September 23, 2010) Johnson & Johnson NYSE:JNJ moved up by 0.05% closed at $61.97 with total traded volume of 9.35 million shares for ...and more »
TopNews Arab EmiratesJohnson & Johnson (NYSE:JNJ) FDA DealStock BriefingsIf you believe this is a good time to make a play on the Johnson & Johnson (NYSE:JNJ) shares, make sure you do it at the right price. ...Johnson & Johnson investor files lawsuit alleging securities laws violationsPRLog.Org (press release)Regulators Probe FDA Over Go Ahead For Phantom Johnson & Johnson Motrin Recall ...Comtex SmartrendTrouble Brewing At Johnson & Johnson? (JNJ)The Market Financialall 420 news articles »
US pharmaceutical giant Johnson & Johnson (NYSE:JNJ) announced that it was engaged in advanced talks to buy all the shares of Dutch vaccine firm Crucell NV (NASDAQ:CRXL) it doesn't already own, according to a joint statement from the companies. According to terms being discussed, J&J would make an all-cash bid to buy outstanding equity of Crucell it didn't already own for 1.75 billion euros ($2.29 billion USD), which represents a purchase price of 24.75 euros per share. Shares of Crucell jumped 58% on the news in Zurich. Through an affiliate, J&J already own 17.9% of the Leiden, Netherlands-based vaccine maker. J&J and Crucell said in a statement."The companies expect that Crucell's strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for Johnson & Johnson in the vaccine market," The companies said that once the deal closes, Crucell will be the base for J&J's vaccines within the company. SmarTrend currently has Crucell NV in an Uptrend and is currently monitoring these developments and will alert subscribers to any change of trend.
Good Morning. It's Friday, September 17, 2010. At this hour, US equity futures are up. Overseas, the Asian markets advanced, while the European markets are higher. Johnson & Johnson (JNJ) and Crucell NV (CRXL) announced that they are in advanced negotiations for a potential public offer by J&J for all outstanding ordinary shares of Crucell not already held by J&J. J&J currently holds approximately 17.9% of the outstanding shares of Crucell. Under the terms of the negotiations, which are at an advanced stage, J&J would acquire all outstanding equity of Crucell that it does not already own for approximately EU1.75B, which represents a purchase price of EU24.75 per share. The public offer would be an all cash transaction...The board of Texas Instruments (TXN) authorized the company to repurchase an additional $7.5B of its common stock. This is in addition to the $1.3B in repurchase authorizations remaining at the end of June. Also, Texas Instruments increased its dividend 8%. The company plans to raise its quarterly cash dividend 1c per common share. TI's new quarterly dividend will be 13c per share of common stock, resulting in annual dividend payments of 52c per common share...Massey Energy (MEE) sees 2010 results to be at low end of previous guidance...
Pharmaceutical and health-care companies: The biggest stock bargainsnewjerseynewsroom.comNot only do many of these stocks seem like bargains, but some were recently paying nice dividends: Novartis, 3.3%; JNJ, 3.6%; Pfizer, 4.4%; Abbott, 3.5%; ...
Beginners guide to investing: Part 1Motley Fool (blog)Now, this example is very, very simple, but this very basic concept is what pro's use everyday to value companies like JNJ, AAPL, XOM.....etc. ...
Weekly News Roundup: Johnson & Johnson (NYSE:JNJ)eMoneyDaily (blog)... with the special drug, abiraterone acetate. We will be monitoring the Johnson & Johnson (NYSE:JNJ) stock price for developments over the next few weeks.
Stocks Are Up 6% in Early SeptemberBarron'sDIVERSIFIED HEALTH-CARE giant Johnson & Johnson (JNJ) has been hit by a series of manufacturing and operational woes since spring, dropping its stock 10%. ...and more »
Forbes (blog)Getting Down And Dirty With The DowForbes (blog)JNJ fits the bill. Its earnings per share have declined just twice in the past ten years, with both dips being minor. It has enough annual earnings (more ...and more »
Johnson and Johnson (JNJ) 9/10/10 PriceWatch Alert Support At Around $58.93Market Intelligence CenterSo far the stock has hit a 52-week low of $56.86 and 52-week high of $66.20. Johnson and Johnson stock has been showing support around 58.93 and resistance ...and more »
"Johnson & Johnson (NYSE:JNJ) is donating $200 million in cash and medicine to a United Nations program that was created to improve the health and lives of people in poor countries. The five-year program is called ""Every Mother, Every Child,"" and is meant to help almost 400 million women and children in developing countries. Johnson & Johnson will donate its medicine for treating intestinal worms in children, send pregnant women information on prenatal health, and work to make childbirth safer. The company will also research new treatments for the AIDS virus and tuberculosis, which disproportionately affect women and children in developing countries. ""It's a natural extension of our commitment to improve the health of mothers and children everywhere,"" Johnson & Johnson CEO Bill Weldon said in prepared remarks. ""For several decades, we've worked in partnership with dozens of nonprofits and governments in every region of the world to help treat and prevent diseases that place mothers and children at risk.""SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56, since then the stock fell 4.2%. We are now watching for any positive developments that could result in a new uptrend signal.
Johnson and Johnson (JNJ) 9/9/10 PriceWatch Alert With $53.90 Break EvenMarket Intelligence CenterSo far the stock has hit a 52-week low of $56.86 and 52-week high of $66.20. Johnson and Johnson stock has been showing support around 58.16 and resistance ...and more »
JNJ Bullish SignsTradersHuddle.comJNJ's recent stock range has been formed by a trough where calculated support was defined at $56.86 and by a peak that established the resistance level at ...and more »
The Star-Ledger - NJ.comStock Picks: Best Buy, Bristol-Myers Squibb, MGM ResortsBusinessWeek(MRK) and Johnson & Johnson (JNJ) have recently presented "solid data" in their respective hepatitis C programs, "so BMY almost certainly felt a need to ...Bristol-Myers Squibb Company Reaches 52-Week High; BMY, JNJ, AZNLearning MarketsBristol-Myers Squibb To Buy Biotech ZymoGenetics For $836MWall Street Journalall 489 news articles »
Johnson and Johnson (JNJ) 9/7/10 PriceWatch Alert With $53.83 Break EvenMarket Intelligence CenterSo far the stock has hit a 52-week low of $56.86 and 52-week high of $66.20. Johnson and Johnson stock has been showing support around 58.31 and resistance ...and more »
"Bayer and Johnson & Johnson (NYSE:JNJ) released positive data Tuesday on their blood-thinner Xarelto, reports MarketWatch. Shares of Johnson & Johnson were trading down at $57.20 earlier in the day, despite the news.SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56, since then the stock fell 8.8%. We are now watching for any positive developments that could result in a new uptrend signal."
Johnson & Johnson's (NYSE:JNJ) artificial joint business is recalling two hip replacement products, which is the company's 11th recall since September. DePuy Orthopaedics Inc. said it is recalling two hip replacement products because new data shows higher-than-expected rates of patients needing a second hip replacement procedure. One in eight patients needed a revision surgery within five years, which is required when an artificial joint doesn't fit perfectly, causing pain and difficulty walking. David Floyd, president of DePuy Orthopaedics said, ""We are committed to assisting patients and healthcare providers by providing information through multiple channels and paying for the cost of doctor visits, tests and procedures associated with the recall.""SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56, since then the stock fell 7.5%. We are now watching for any positive developments that could result in a new uptrend signal.
"Johnson & Johnson (NYSE:JNJ) has been warned via a letter from the US Food & Drug Administration (FDA) that the company has been marketing two of its products in an improper manner, MarketWatch reports Tuesday. In a letter to the company, the FDA has told Johnson & Johnson to halt the marketing of its TruMatch Personalized Solutions system and the Corail Hip System until the products gain regulatory approval. The company's DePuy Orthopedics unit sells the two products.SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56, since then the stock fell 7.4%. We are now watching for any positive developments that could result in a new uptrend signal. Shares of the health care products manufacturer are trading down 1.55% Tuesday afternoon at $57.96."
Johnson & Johnson (NYSE:JNJ) has accrued a $600 million price tag for recalls from its McNeil Consumer Healthcare unit, from products including children's allergy and pain medications. The company cut $200 million Q2 sales and will slash about $600 million from 2010 sales due to the recalls as well. ""With respect to any potential collateral damage, it is too early for us to comment on that,"" said chief financial officer Dominic Caruso. ""Obviously, our businesses have been very good over the years [at] innovating and assuring [that] consumers get the kind of products that they expect and at the quality they expect.""SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56; since then, the stock fell 6.7%. We are now watching for any positive developments that could result in a new uptrend signal. Johnson & Johnson is currently below its 50-day moving average (MA) of $60.24 and below its 200-day MA of $62.61. In the last five trading sessions, the 50-day MA has fallen 0.74% while the 200-day MA has slid 0.03%. Shares of the health care products manufacturer are trading down 1.95% Tuesday afternoon at $58.41.
Johnson & Johnson reporting it's 2Q earnings before the opening bell this morning, the company hosted a conference call to discuss what's ahead for the healthcare sector stock. With me to discuss the numbers and what's next is Ben Yeoh of Atlantic Equities research.
Themajor US equity indices are trading lower Tuesday as investors grow worried about the strength of the economic recovery following weaker-than-expected revenue reports from large companies. The Commerce Department reported that home construction fell last month to the lowest level since October. In corporate news, Johnson & Johnson (NYSE:JNJ) shares are trading 2.60% lower at $58.02 after the company reported flat revenues, missing consensus estimates. IBM (NYSE:IBM) shares are trading 4.15% lower at $124.40 following disappointing results. Goldman Sachs (NYSE:GS) also reported lower revenues as its trading business was hurt by weakness during the spring. The Dow Jones Industrial Average (DJI) is trading 0.90% lower at 10063.46, the S&P500 (INX) is trading 0.66% lower at 1064.16, and the Nasdaq Composite (IXIC) is trading 0.99% lower at 2176.41.
Johnson & Johnson (NYSE:JNJ) reported fiscal Q2 net income of $3.4 billion, or $1.23 per share. Excluding certain items, net earnings for the quarter were $3.4 billion, or $1.21 per share. On average, analysts expected EPS of $1.21.Revenues rose 0.6% year-over-year to $15.3 billion. On average, analysts expected revenues of $15.64 billion. CEO William C. Weldon said, "Our second-quarter results include strong growth in a number of our recently launched products which contributed to solid earnings. Remedial actions to address the product quality issues at McNeil Consumer Healthcare are ongoing and of high importance. At the same time, we continue to make significant investments in acquisitions, strategic partnerships and in advancing our pipeline, positioning us well for future growth." SmarTrend alerted subscribers to take profits in Johnson & Johnson on May 06, 2010 at $62.56, since then the stock fell 4.7%. We are now watching for any positive developments that could result in a new uptrend signal.
A joint consumer medicines venture between Johnson & Johnson (JNJ) and Merck (MRK) received a citation by the US Food and Drug Administration following the agency's recent inspection of a plant for the joint venture, according to Reuters. The citation, a Form 483, lists any problems found during an inspection, the report said. Johnson & Johnson shares are up 0.19%, or $0.11, to $59.55. Merck shares are down $0.01. or 0.03, to $35.90.
Johnson & Johnson (JNJ) is expected to report Q2 earnings Tuesday, July 20 before the market open with a conference call scheduled for 8:30 am ET. Analysts are looking for EPS of $1.21on revenue of $15.66B. The consensus range is $1.16-$1.25 for EPS, and $15.38B-$15.98B for revenue, according to First Call. Positive catalysts for this quarter may come from the drug giant's Ethicon and diagnostics units as well as from orthopedics and diabetes. Efficiencies in manufacturing should add to gross margin expansion this quarter. Pharmaceutical sales were most likely held in check by generic erosion this quarter and consumer goods volumes may have been hampered by recent recalls.
7/12/2010-Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Micrus Endovascular Corporation (NASDAQ:MEND) in a cash for stock exchange deal. Under terms of the agreement, shareholders of Micrus will receive $23.40 for each outstanding share they own. The value of the deal as of the anticipated closing date is estimated to be approximately $480 million, based on Micrus' current 20.5 million shares outstanding.
7/9/2010-Johnson & Johnson (NYSE:JNJ) recalled more Tylenol and other over-the-counter drugs Thursday after they were tied to musty odor, furthering the recall they launched in January. J&J's McNeil Consumer Healthcare Unit indicated that the latest recall included 21 lots of medications, which included Tylenol for children and adults, Benadryl allergy tablets and Motrin. The tablets were sold in the United States, Fiji, Guatemala, the Dominican Republic, Puerto Rico, Trinidad and Tobago and Jamaica, J&J said. Shares of Johnson & Johnson are trading 0.6% lower in premarket trading.
Jul 8, 2010 -- Johnson & Johnson (JNJ) is edging higher in afternoon trading, up near 1% and its session high of $61.10, despite expanding a recall of Tylenol and other drugs because of a musty or moldy smell. The recall affects the United States, Puerto Rico, Fiji, Guatemala, the Dominican Republic, Trinidad and Tobago and Jamaica. The drugs that are Benadryl, Children's Tylenol, Motrin IB, Tylenol Extra Strength, Tylenol Day & Night, and Tylenol PM. The odor was linked to a chemical in shipping pallets and about 70 people have been sickened by the smell, the company said. "
Johnson & Johnson's (JNJ) said Thursday it won US Food and Drug Administration approval to begin selling a new contact lens called 1-Day Acuvue TruEye T. The product will be available from eye care professionals later in June.
Johnson & Johnson (JNJ) shares are higher as a US Congressional committee charged with investigating the recent recall of of children's medicine is "deeply concerned" on the drug makers cooperation level, a Reuters report said. The committee held hearings last month. Johnson and Johnson shares were up $0.33, or 0.57%, to $58.50.
9:00 AM, Jun 9, 2010 -- Dow Jones US Health Care Index: 293.84 Tuesday regular session close Top Health Care Stocks JNJ: +0.19% PFE: +0.21% MRK: -0.06% ABT: -0.68% AMGN: 0.00% Health care shares are mixed before the bell, with Allscripts-Misys Healthcare Solutions (MDRX) buying Eclipsys (ECLP) for $1.3 billion in stock. The deal will create a software company that will allow US doctors and hospitals to share patients' records. Regeneron Pharmaceuticals (REGN) said its gout drug met its main goal of preventing gout attacks in a late-stage study. The drug Arcalyst did not, however, improve gout-related pain in another study.
Johnson & Johnson (JNJ) is in the hot seat with US lawmakers, who are reportedly demanding records from two contractors allegedly hired by the drug maker to buy back defective Motrin tablets, Bloomberg reported. Johnson & Johnson shares are down $1.10, or 1.84%, to $58.67.
5/26/2010- The FDA has received more than 700 complaints about health problems in infants and children that have been given Johnson & Johnson (NYSE:JNJ) medications, including 30 reported deaths, but regulators have yet to find a direct link, according to a Reuters report. Johnson & Johnson took more than 40 nonprescription products off shelves in April, including Children's Tylenol, which was considered the largest recall of such children's medications to the congressional staff. A US House of Representatives hearing to examine manufacturing lapses at J&J plants that led to the recall is scheduled for Thursday. Johnson & Johnson shares are currently trading 0.65% lower at $59.96.
5/25/2010 - The US Food and Drug Administration (FDA) requested additional inspections and an outside audit of Advanced Sterilization Products, a unit of Johnson & Johnson's (NYSE:JNJ) Ethicon Inc, following multiple problems with manufacturing and safety hazards. An FDA warning letter to the Irvine, California-based Johnson & Johnson unit was made public Tuesday, citing issues including failures to verify the necessary design alterations to ensure proper device operations. Officials for Johnson & Johnson and Ethicon have not commented on the second inspection, and FDA officials said that Ethicon's responses have not been adequate so far. Shares of Johnson & Johnson are trading down 1.21% at $59.59.
Dow Jones US Health Care Index: 316.18 Monday regular session close Top Health Care Stocks JNJ: -1.16% PFE: -1.12% MRK: -1.55% ABT: -1.19% AMGN: -1.93% Health care issues are weaker ahead of the bell Tuesday, with GlaxoSmithKline to pay about $60 million in the first settlements of lawsuits alleging that its Avandia diabetes drug causes heart attacks and strokes, according to Bloomberg. NicOx (NCOX) is weaker as the FDA questioned the heart benefits of the French drugmaker's experimental pain drug naproxcinod.
op Health Care Stocks JNJ: -0.77% PFE: -0.35% MRK: +0.06% ABT: -0.10% AMGN: 0.00% Health care issues are mostly lower before the bell Thursday, with Omnicare (OCR) reporting first quarter net earnings of $50.9 million, or 43 cents a share, compared to $30.9 million, or 26 cents a share, posted a year ago. The gains were largely due to lower costs and charges, the drug maker said. Canada's Biovail (BVF) reported first quarter results that beat expectations, even though it posted a loss. It reported a net loss of $3.2 million, or a profit of 31 cents a share excluding one-time items, compared to a profit of $39 million, or 25 cents a share. Analysts polled by Thomson Reuters had expected 27 cents a share.
The diversified health care giant operates in three segments through more than 250 operating companies located in some 60 countries. Its Pharmaceuticals division makes drugs for an array of ailments, such as neurological conditions, blood disorders, autoimmune diseases, and pain. Top sellers are psoriasis drug Remicade and schizophrenia medication Risperdal. J&J's Medical Devices and Diagnostics division offers surgical equipment, monitoring devices, orthopedic products, and contact lenses, among other things. Its Consumer segment makes over-the-counter drugs and products for baby, skin, and oral care, as well as first aid and women's health.
the Wall Street Journal reports...General Growth Properties (GGP) prefers a revised proposal led by Brookfield Asset Management (BAM) for exiting bankruptcy and not one from Simon Property Group (SPG), according to the Washington Post...The criminal investigation of Goldman Sachs (GS) launched by the Justice Department encompasses areas other than the activities for which the firm has been charged by the SEC, , the Nikkei reports...Honda (HMC) has issued the recall of about 167000 Acura TSX sedans in the US due to a power-steering hose that could deteriorate and lead to fire or smoke. The recall affects models from 2004-2008... the Wall Street Journal reports...The US military will become more competitive worldwide for raw materials as competition grows affecting costs and availability, and as it pertains to national security, Barron's: HP's (HPQ) entrance into the smartphone market with its acquisition of Palm (PALM) makes things tough for others... Johnson & Johnson's (JNJ) earnings growth should accelerate, Barron's says. Investors taking a bearish view on Johnson & Johnson shares thinking they are fairly valued based on so-so growth prospects, should take another look... The market values of the BP (BP), Transocean (RIG), Anadarko Petroleum (APC) and other companies involved in the potentially disastrous recent oil spill in the Gulf of Mexico, have declined by a total of more than $40B. Barron's feels Wall Street was too hard on BP and Transocean and that the ...
Johnson & Johnson (NYSE:JNJ) units Ortho-McNeil and Ortho-McNeil-Janssen will pay $81.5 million to settle criminal and civil charges. The charges are related to an epilepsy drug that the units promoted, Topamax, for unapproved psychiatric uses, according to the Department of Justice. Ortho-McNeil will be responsible for paying $6.1 million and Ortho-McNeil Janssen will pay $75.4 million. Johnson & Johnson shares are currently trading 0.77% higher at $65.12.
Business News, Stock Market News, Analysis & Dividend Reports, Stock Dividends, Stock Market Trading News, Market Wrap-up, Johnson & Johnson (NYSE: JNJ), Walgreens (NYSE:WAG), Unum Group (NYSE: UNM), Pitney Bowes Inc. (NYSE: PBI)